

DAFTAR PUSTAKA

- Afrianti, R., Larucy, F., & Widayana, H. (2023). Interaksi Obat Anti Tuberkulosis pada Pasien Tuberkulosis Paru. *Jurnal Kesehatan Perintis* 10 (1): 53-59.
- Andayani. 2017. *Prediksi Kejadian Penyakit Tuberkulosis Paru Berdasarkan di Kabupaten Ponorogo Tahun 2016 – 2020*.
- Arfan Sanusi, dan, & Nasir, M. (2020). TUBERKULOSIS MULTIDRUG-RESISTANT PADA DIABETES MELITUS TIPE 2 (Multidrug-Resistant Tuberculosis in Diabetes Mellitus Type 2). In *Jurnal Medical Profession (MedPro)* (Vol. 2, Issue 3).
- Baker, M. A., Harries, A. D., Jeon, C. Y., Hart, J. E., Kapur, A., Lönnroth, K., Ottmani, S. E., Goonesekera, S. D., & Murray, M. B. (2011). The impact of diabetes on tuberculosis treatment outcomes: A systematic review. *BMC Medicine*, 9. <https://doi.org/10.1186/1741-7015-9-81>
- Castro-Rodriguez, B., Franco-Sotomayor, G., Orlando, S. A., & Garcia-Bereguian, M. Á. (2024). Molecular epidemiology of *Mycobacterium tuberculosis* in Ecuador: Recent advances and future challenges. In *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases* (Vol. 37). Elsevier Ltd. <https://doi.org/10.1016/j.jctube.2024.100465>
- Caterina, P., Paolo Antonello, D., Chiara, G., Chiara, C., Giacomo, L., Antonio, S., Sarro Giovambattista, D., & Luca, G. (2013). Pharmacokinetic drug-drug interaction and their implication in clinical management. In *Journal of Research in Medical Sciences*.
- Chai, Q., Wang, L., Liu, C. H., & Ge, B. (2020). New insights into the evasion of host innate immunity by *Mycobacterium tuberculosis*. In *Cellular and Molecular Immunology* (Vol. 17, Issue 9, pp. 901–913). Springer Nature. <https://doi.org/10.1038/s41423-020-0502-z>.
- Chandra. 2010. Nutrition and immunity. American: *The American Journal Of clinical Nutrition*.
- Corry, K., & Hardman, J.G. (2017). Mechanisms of Drug Interactions: Pharmacodynamics and Pharmacokinetics. *Anaesthesia and Intensive Care Medicine* 18:7. Elsevier Ltd.

- Dewanty, L., K., Haryanti, T., dan Puji Kurniawan, T. (2016). *KEPATUHAN BEROBAT PENDERITA TB PARU DI PUSKESMAS NGUNTORONADI I KABUPATEN WONOGIRI*.
- Dinkes DIY. (2024). *Buku Data Kesehatan 2023*. Yogyakarta: Dinas Kesehatan Yogyakarta.
- Drugs.com. (2025). *Drug Interactions Checker*. Drugs.com. https://www.drugs.com/drug_interactions.html
- Gitawati, R. (2008). Interaksi Obat dan Beberapa Implikasinya. *Media Litbang Kesehatan*, XVIII (4).
- Haryani, L., Ramadhani, N. R., Meirawan, R.F., Burmanajaya, B. Gambaran Faktor Risiko Pasien HIV dengan Tuberkulosis di RSUD Kota Bogor. (2023). *Jurnal Epidemiologi Kesehatan Indonesia*, 7(2). <https://doi.org/10.7454/epidkes.v7i2.1085>
- Hamada, Y., Getahun, H., Tadesse, B. T., & Ford, N. (2021). HIV-associated tuberculosis. In *International Journal of STD and AIDS* (Vol. 32, Issue 9, pp. 780–790). SAGE Publications Ltd. <https://doi.org/10.1177/0956462421992257>
- Joshi, R., Reingold, A. L., Menzies, D., & Pai, M. (2006). Tuberculosis among Health-Care Workers in Low-and Middle-Income Countries: A Systematic Review. *PLoS Medicine | Www*, 3, 12–494. <https://doi.org/10.1371/journal.pmed>
- Kemenkes RI. (2020). *Pedoman Nasional Pelayanan Kedokteran Tata laksana Tuberkulosis*. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kemenkes RI. (2022). *Laporan Program Penanggulangan Tuberkulosis 2021*. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kemenkes RI. (2023). *Buku Pegangan Operasional Pengobatan Tuberkulosis Resistan Obat dengan Panduan BPAL/M*. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Krishnamurthy, P., Sunil Kadam, & Jacob Matthews. (2022). Drug Interactions: A Review. *International Healthcare Research Journal*, 6(2), Rv1-R5. <https://doi.org/10.26440/IHRJ/0602.0539>
- Laili, F., Ronoatmodjo, S., & Murtiani, F. (n.d.). Ko-Infeksi TB-HIV terhadap Kegagalan Pengobatan Pasien Tuberkulosis Resistan Obat di Indonesia TB-HIV Co-Infection for Treatment Failure of Drug-Resistant Tuberculosis Patients in Indonesia. In *The Indonesian Journal of Infectious Disease* (Vol. 10, Issue 2).

- Lemeshow, S., Hosmer Jr, D.W., Klar, J., Lwanga, S.K. (1997). *Besar Sampel Dalam Penelitian Kesehatan*. Yogyakarta: Gadjah Mada University Press.
- Lexicomp, 2023, Interaction Analysis, diakses dari www.online.lexi.com.
- Maison, D. P. (2022). Tuberculosis pathophysiology and anti-VEGF intervention. In *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases* (Vol. 27). Elsevier Ltd. <https://doi.org/10.1016/j.jctube.2022.100300>
- Marais BJ, Donald PR. The natural history of tuberculosis infection and disease in children. In: Schaaf HS, Zumla A, editors. *Tuberculosis: A Comprehensive Clinical Reference*. Elsevier Health Sciences; 2009.
- Marsh, Daphne. (2023). Adverse Drug Reactions. MSD Manual. Diakses dari <https://www.msdmanuals.com/home/drugs/adverse-drug-reactions/severity-of-adverse-drug-reactions>
- Martens, G. W., Arian, M. C., Lee, J., Ren, F., Greiner, D., & Kornfeld, H. (2007). Tuberculosis susceptibility of diabetic mice. *American Journal of Respiratory Cell and Molecular Biology*, 37(5), 518–524. <https://doi.org/10.1165/rcmb.2006-0478OC>
- Mei, F. O., Ayu, I., Parthasutema, M., & Wintariani, N. P. (2020). *BALI INTERNATIONAL SCIENTIFIC FORUM Faktor-Faktor Yang Mempengaruhi Kegagalan Terapi Pasien TB Paru di Puskesmas Labuan Bajo*. 1(1).
- Molina, P. E., Happel, K. I., Zhang, P., Kolls, J. K., & Nelson, S. (n.d.). *ALCOHOL AND HEALTH FOCUS ON: ALCOHOL AND THE IMMUNE SYSTEM*.
- Mutia Rahman, M., Setyawati, T., & Dwi Wahyuni, R. (2023). MEKANISME OAT DALAM TUBUH YANG MENGAKIBATKAN RISIKO DILI (drug-induced liver injury): LITERATURE REVIEW OAT MECHANISM IN THE BODY THAT CAUSED THE RISK OF DILI (drug-induced liver injury): LITERATURE REVIEW. In *Jurnal Medical Profession (MedPro)* (Vol. 5, Issue 1).
- Narasimhan, P., Wood, J., Macintyre, C. R., & Mathai, D. (2013). Risk factors for tuberculosis. In *Pulmonary Medicine*. Hindawi Publishing Corporation. <https://doi.org/10.1155/2013/828939>
- Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivistö, K. T. (2003). Pharmacokinetic Interactions with Rifampicin Clinical Relevance. In *Clin Pharmacokinet* (Vol. 42, Issue 9).

- PDPI. (2021). *Tuberkulosis: Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Jakarta: Perhimpunan Dokter Paru Indonesia.
- Rahayu, F. P., & Susilawati, Y. (n.d.). *IDENTIFIKASI INTERAKSI OBAT PADA RESEP TENTANG GANGGUAN PERNAPASAN DI BULAN FEBRUARI 2023 DI APOTEK KOTA BANDUNG* (Vol. 21). www.medscape.com
- Rehm, J., Samokhvalov, A. V., Neuman, M. G., Room, R., Parry, C., Lönnroth, K., Patra, J., Poznyak, V., & Popova, S. (2009). The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. *BMC Public Health*, 9. <https://doi.org/10.1186/1471-2458-9-450>
- Reyaan, I. B. M., Kuning, C., & Adnyana, I. K. (2021). Studi Potensi Interaksi Obat pada Resep Polifarmasi di Dua Apotek Kota Bandung. *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, 11(3), 145. <https://doi.org/10.22146/jmpf.56931>
- Rika Veryanti, P., Putu, N., Dewi, K., & Pertiwi, D. (n.d.). *Potensi Interaksi Obat Anti Tuberkulosis di Instalasi Rawat Inap RSUD X Jakarta Periode 2016*.
- Rodrigues, A. T., Stahlschmidt, R., Granja, S., Pilger, D., Falcão, A. L. E., & Mazzola, P. G. (2017). Prevalence of potential drug-drug interactions in the intensive care unit of a Brazilian teaching hospital. *Brazilian Journal of Pharmaceutical Sciences*, 53(1). <https://doi.org/10.1590/s2175-97902017000116109>
- Rolo, M., González-Blanco, B., Reyes, C. A., Rosillo, N., & López-Roa, P. (2023). Epidemiology and factors associated with Extra-pulmonary tuberculosis in a Low-prevalence area. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, 32. <https://doi.org/10.1016/j.jctube.2023.100377>
- Smith, I. (2003). Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. In *Clinical Microbiology Reviews* (Vol. 16, Issue 3, pp. 463–496). <https://doi.org/10.1128/CMR.16.3.463-496.2003>
- Sukatemin. (2022). Faktor yang berkorelasi dengan Kejadian Drop Out pada Pengobatan Tuberculosis Paru, *Indonesian Health Issue*, 1 (2).
- Sunjaya, A. P., & Amelia, D. A. R. (2019). Recurrent Mycobacterium tuberculosis infection in systemic lupus erythematosus patient: case report and review. *Jurnal Kedokteran Dan Kesehatan Indonesia*, 10(1), 97–104. <https://doi.org/10.20885/jkki.vol10.iss1.art14>
- Tatro, D. S., 2015, *Drug Interaction Facts*, Wolters Kluwer Health Inc., California.

- Tobin, E.H. & Tristram, D. (2024). *Tuberculosis*. StatPearls. <https://www.ncbi.nlm.nih.gov/books/NBK441916/>
- Van Zyl Smit, R. N., Pai, M., Yew, W. W., Leung, C. C., Zumla, A., Bateman, E. D., & Dheda, K. (2010). Global lung health: The colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. In *European Respiratory Journal* (Vol. 35, Issue 1, pp. 27–33). <https://doi.org/10.1183/09031936.00072909>
- WHO. (2023). *Global Tuberculosis Report 2023*. World Health Organization.
- Zhang, Y. S., Li, Q., He, B. S., Liu, R., & Li, Z. J. (2015). Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper gastrointestinal bleeding after endoscopy: A meta-analysis. *World Journal of Gastroenterology*, 21(20), 6341–6351. <https://doi.org/10.3748/wjg.v21.i20.6341>
- Zhuang, X., Li, L., Liu, T., Zhang, R., Yang, P., Wang, X., & Dai, L. (2022). Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: A review. In *Frontiers in Pharmacology* (Vol. 13). Frontiers Media S.A. <https://doi.org/10.3389/fphar.2022.1037814>